A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations

• All patients participating in this clinical trial must have progressed following standard therapy, or for whom, in the opinion of the Investigator, no effective standard therapy exists, is tolerated or appropriate.

• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

• Presence of at least one measurable lesion according to RECIST v1.1.

• Documented MAPK alteration

⁃ Additional inclusion criteria for the Dose Expansion part: LXH254 in combination with PDR001:

• Patients with confirmed KRAS-mutated NSCLC

• Patients with confirmed NRAS-mutated melanoma (cutaneous melanoma only)